Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,274 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study of ustekinumab in Japanese patients with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments.
Kawahata K, Ishii T, Gono T, Tsuchiya Y, Ohashi H, Yoshizawa K, Zheng R, Ayabe M, Nishikawa K. Kawahata K, et al. Among authors: zheng r. RMD Open. 2023 Aug;9(3):e003268. doi: 10.1136/rmdopen-2023-003268. RMD Open. 2023. PMID: 37652554 Free PMC article. Clinical Trial.
Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
Ohtsuki M, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Ohtsuki M, et al. Among authors: zheng r. J Dermatol. 2018 Sep;45(9):1053-1062. doi: 10.1111/1346-8138.14504. Epub 2018 Jun 15. J Dermatol. 2018. PMID: 29905383 Free PMC article. Clinical Trial.
Efficacy of guselkumab in a subpopulation with pustulotic arthro-osteitis through week 52: an exploratory analysis of a phase 3, randomized, double-blind, placebo-controlled study in Japanese patients with palmoplantar pustulosis.
Yamamoto T, Fukuda K, Morita A, Kimura T, Morishima H, Goto R, Zheng R, Terui T. Yamamoto T, et al. Among authors: zheng r. J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2318-2329. doi: 10.1111/jdv.16355. Epub 2020 May 15. J Eur Acad Dermatol Venereol. 2020. PMID: 32173916 Free PMC article. Clinical Trial.
Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.
Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Sano S, et al. Among authors: zheng r. J Dermatol. 2018 May;45(5):529-539. doi: 10.1111/1346-8138.14294. Epub 2018 Mar 22. J Dermatol. 2018. PMID: 29569397 Free PMC article. Clinical Trial.
Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI).
Hisamatsu T, Kim HJ, Motoya S, Suzuki Y, Ohnishi Y, Fujii N, Matsushima N, Zheng R, Marano CW. Hisamatsu T, et al. Among authors: zheng r. Intest Res. 2021 Oct;19(4):386-397. doi: 10.5217/ir.2020.00080. Epub 2020 Dec 1. Intest Res. 2021. PMID: 33249802 Free PMC article.
4,274 results